Under the Microscope - Articles and news items

Under the Microscope: John Comer, Sirius Analytical

Issue 6 2012 / 18 December 2012 / Helen Bahia, Editor, European Pharmaceutical Review

John Comer, Chief Scientific Officer at Sirius Analytical, discusses particle size analysis and characterisation.

Sirius Analytical was founded in 1989 with the goal to become a world-class manufacturer of innovative instrumentation for chemical analysis. Today, Sirius Analytical makes instruments to measure the physicochemical properties of drugs, specifically pKa, logP, solubility and dissolution. The current gold standard for Sirius Analytical is the SiriusT3, a third generation physchem measurement system.

“When we were developing the SiriusT3, we knew that scientists had less sample weight available to make physchem measure ments, so we miniaturised key components to facilitate titration experiments in just 1.5 mL volumes,” explains John Comer, Chief Scientific Officer, Sirius Analytical. “This led to the greatest benefit of the SiriusT3; it makes pKa, logP and solubility measurements using quite small amounts of sample. We can measure pKa by the pH-metric technique using half a milligram of sample while we need only a few micrograms to measure pKa by UV. The other benefit of a third generation technology is that we learned a lot about how to improve performance from customers and users of the first two generations and all that experience is built into the SiriusT3.”

Under the microscope: Steve Delity

Issue 4 2011 / 31 August 2011 / Steve Delity, CEO, Rapid Micro Biosystems

Rapid Micro Biosystems is a privately owned, venture backed company with headquarters in Bedford, Massachusetts. Since launching its GrowthDirect™ System in 2008, the company has now moved into Europe with the opening of its new demo centre in Darmstadt, Germany in June 2011. So, how does CEO Steve Delity view the current situation in the pharmaceutical industry? “The power of pharmaceutical research and development is so massive that there will always be blockbusters, but will we see the prevalence, the frequency, the number of blockbusters we’ve had in the past? It’s a more efficient deployment of resources to take known drugs and look at whether it’s possible to increase their efficacy or decrease the side effects. The hunt for the next big blockbuster will always be there, but you can spend a lot of money and come up with nothing in the end, which is a huge risk.”


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...